BonfanteSDella GiustinaADanielskiLGDenicolTJoaquimLBiehlEet al
Michaelsen, MD, with the department of clinical medicine at Aarhus University in Denmark, and colleagues
In 2024, BSF Lifesciences launched a bio-similar human insulin, which is Semaglutide, a leading GLP-1 therapy, he said, adding that it is a new hope with affordable and accessible treatment for patients with diabetes and the metabolic syndrome
Clostridium butyricum strains suppress experimental acute pancreatitis by maintaining intestinal homeostasis
Wang L, Berger NA, Kaelber DC, Xu R
Unlike some other diabetes medicationssuch as thiazolidinediones (glitazones), which are known to cause oedemaGLP-1 agonists are more commonly associated with dehydration (due to gastrointestinal side effects) rather than fluid retention